Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease.
about
Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's DiseaseParkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic?Decrease in Aβ42 predicts dopa-resistant gait progression in early Parkinson disease.Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.Premotor and nonmotor features of Parkinson's disease.Cognition and gait show a selective pattern of association dominated by phenotype in incident Parkinson's diseaseIntegrative network analysis unveils convergent molecular pathways in Parkinson's disease and diabetes.Cerebrospinal fluid Aβ42 levels and APP processing pathway genes in Parkinson's disease.CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report.Global cognitive function and processing speed are associated with gait and balance dysfunction in Parkinson's diseasePhenotype of postural instability/gait difficulty in Parkinson disease: relevance to cognitive impairment and mechanism relating pathological proteins and neurotransmitters.What can biomarkers tell us about cognition in Parkinson's disease?What are the priorities in Parkinson's disease clinical research? A focus on motor complications, gait and cognition.Imaging the role of amyloid in PD dementia and dementia with Lewy bodies.Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.Current Challenges Towards the Development of a Blood Test for Parkinson's Disease.Nonmotor features of Parkinson's disease subtypes.Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease.Association of a BACE1 Gene Polymorphism with Parkinson's Disease in a Norwegian Population.Cognitive function and other non-motor features in non-demented Parkinson's disease motor subtypes.Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease?Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson's disease.Gait and balance in Parkinson's disease subtypes: objective measures and classification considerations.
P2860
Q26744782-4CEBEB85-C709-4B60-8A66-C1D166D481BAQ27686837-594D6338-38E0-40D1-BBCD-11BB276F41A5Q28083203-3748AE30-FAE1-4E80-82D0-7F5009311CC1Q33574058-8C332B93-CB3B-48F5-9657-6C0B9702E388Q33666297-2EB68FDF-8A59-4F86-8E29-84F4F7441C55Q34274224-ECE82C1D-5689-48B5-8BA9-A44E59CB86C7Q34382051-9E42C240-DDE0-44D0-B7E2-8A88362FAB9BQ35078279-644FBE78-76EB-44F4-9134-B17CE3EE125FQ35772659-741AD5FD-398D-4EAD-9CFA-00BB6FECD625Q36169215-9C0E9CBB-8275-464D-AD4B-4533BB145838Q37374495-50ABA959-E451-45A8-87B9-1E57678CF5E1Q37717401-9B4F6B93-DB2E-457A-9D98-8C9F0397232FQ38206497-7BBF3E3A-A9C0-43F8-B290-6DB7BA9348BDQ38212033-B02A81A8-3F51-4E08-ABD0-0345A3B4933DQ38228098-9D1C2F7F-6A1D-4A30-A8AB-7E0BD9B8D134Q38271572-F37E899C-C7DD-4347-A9EB-183081416F29Q38603309-BD9163AA-07FD-417D-AF64-9F4AC2EAB08EQ38725286-6EF84850-AF70-4378-A288-5FF5586245B2Q38727963-8FCDAA65-28D2-4305-9654-07A228A6D972Q39366291-C9904576-B018-43A8-860D-C7500BAF959CQ42178133-4EF258AF-5A75-42F0-BD1F-FBC492EDD9C1Q47774821-082EB7FB-0E34-4822-B833-3152F9EEDB14Q48759416-24A4BDDE-5812-445C-A045-F18118453E6CQ50241117-EC4C6779-806D-4045-AD22-5619F19EF97FQ50246695-4455F95C-95CE-42B1-9AF6-992AFBF908F5
P2860
Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Cerebrospinal fluid amyloid-β ...... n de novo Parkinson's disease.
@en
Cerebrospinal fluid amyloid-β ...... n de novo Parkinson's disease.
@nl
type
label
Cerebrospinal fluid amyloid-β ...... n de novo Parkinson's disease.
@en
Cerebrospinal fluid amyloid-β ...... n de novo Parkinson's disease.
@nl
prefLabel
Cerebrospinal fluid amyloid-β ...... n de novo Parkinson's disease.
@en
Cerebrospinal fluid amyloid-β ...... n de novo Parkinson's disease.
@nl
P2093
P50
P356
P1476
Cerebrospinal fluid amyloid-β ...... n de novo Parkinson's disease.
@en
P2093
George F Borm
Jan Petter Larsen
Johannes Lange
Kenn Freddy Pedersen
Mona K Beyer
Turi O Dalaker
Ulf Andreasson
P304
P356
10.1136/JNNP-2012-303808
P407
P50
P577
2012-10-31T00:00:00Z